Xuanzhu Biopharmaceutical Co., Ltd. (HKG:2575)

Market Cap	17.38B
Revenue (ttm)	57.61M +72.0%
Net Income	-273.20M
EPS	-0.59
Shares Out	517.95M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,824,609
Average Volume	2,237,487
Open	33.30
Previous Close	33.56
Day's Range	30.98 - 33.30
52-Week Range	23.82 - 96.90
Beta	n/a
RSI	35.37
Earnings Date	Mar 30, 2026

About Xuanzhu Biopharmaceutical

Xuanzhu Biopharmaceutical Co., Ltd. engages in the development, industrialization, and commercialization of small-molecule chemical drugs and macromolecular biopharmaceuticals in China. Its lead product candidates include Core- KBP-3571 for the treatment of duodenum ulcers; XZP-3287, a CDK4/6 inhibitor for the treatment of HR+/HER2 advanced breast cancer; and XZP-3621, a first-line treatment for patients with anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. The company also develops KM501, a first-in-class HER2/HER2 bisp...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2008
• Employees: 197
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2575

Financial Performance

In 2025, Xuanzhu Biopharmaceutical's revenue was 51.77 million, an increase of 72.03% compared to the previous year's 30.09 million. Losses were -245.51 million, -55.88% less than in 2024.

Financial numbers in CNY